{"entity":{"type":"insider","cik":"0001377202","url":"/insider/0001377202","json_url":"/insider/0001377202.json","name":"Sharp Shalini","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":69,"n_filings":43,"first":"2007-03-14","last":"2024-05-21","span_basis":"filed_date"},"name_variants":[{"name":"Sharp Shalini","source":"filing","n_filings":43,"first_seen":"2007-03-14","last_seen":"2024-05-21"}],"transactions":[{"id":3067234,"accession":"0000914475-24-000138","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000914475-24-000138","line_url":"/filing/0000914475-24-000138#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1106.0,"shares_display":"1,106","price_per_share":141.9018,"price_display":"141.90","price_state":"stated","total_value":156943.3908,"total_display":"156,943.39","shares_owned_after":994.0,"shares_owned_after_display":"994","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-17","filed_date":"2024-05-21","scope":"insider"},{"id":2083882,"accession":"0001209191-20-055172","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-055172","line_url":"/filing/0001209191-20-055172#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (EVP, Finance)","officer_title":"EVP, Finance","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":375.0,"shares_display":"375","price_per_share":87.99,"price_display":"87.99","price_state":"stated","total_value":32996.25,"total_display":"32,996.25","shares_owned_after":97812.0,"shares_owned_after_display":"97,812","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-14","filed_date":"2020-10-16","scope":"insider"},{"id":2181399,"accession":"0001209191-20-047455","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-20-047455","line_url":"/filing/0001209191-20-047455#line-8","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7188.0,"shares_display":"7,188","price_per_share":88.38,"price_display":"88.38","price_state":"stated","total_value":635275.44,"total_display":"635,275.44","shares_owned_after":98187.0,"shares_owned_after_display":"98,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":2181398,"accession":"0001209191-20-047455","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-20-047455","line_url":"/filing/0001209191-20-047455#line-7","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3669.0,"shares_display":"3,669","price_per_share":88.38,"price_display":"88.38","price_state":"stated","total_value":324266.22,"total_display":"324,266.22","shares_owned_after":98187.0,"shares_owned_after_display":"98,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":2181396,"accession":"0001209191-20-047455","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-20-047455","line_url":"/filing/0001209191-20-047455#line-6","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2560.0,"shares_display":"2,560","price_per_share":88.54,"price_display":"88.54","price_state":"stated","total_value":226662.4,"total_display":"226,662.40","shares_owned_after":98187.0,"shares_owned_after_display":"98,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":2181394,"accession":"0001209191-20-047455","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-20-047455","line_url":"/filing/0001209191-20-047455#line-5","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":88.38,"price_display":"88.38","price_state":"stated","total_value":44190.0,"total_display":"44,190.00","shares_owned_after":98187.0,"shares_owned_after_display":"98,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":2181391,"accession":"0001209191-20-047455","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-047455","line_url":"/filing/0001209191-20-047455#line-4","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":461.0,"shares_display":"461","price_per_share":88.24,"price_display":"88.24","price_state":"stated","total_value":40678.64,"total_display":"40,678.64","shares_owned_after":100747.0,"shares_owned_after_display":"100,747","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":2683012,"accession":"0001209191-20-034710","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-034710","line_url":"/filing/0001209191-20-034710#line-4","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2564.0,"shares_display":"2,564","price_per_share":74.01,"price_display":"74.01","price_state":"stated","total_value":189761.64,"total_display":"189,761.64","shares_owned_after":101208.0,"shares_owned_after_display":"101,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-04","filed_date":"2020-06-05","scope":"insider"},{"id":2683003,"accession":"0001209191-20-034710","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-034710","line_url":"/filing/0001209191-20-034710#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10234.0,"shares_display":"10,234","price_per_share":74.23,"price_display":"74.23","price_state":"stated","total_value":759669.82,"total_display":"759,669.82","shares_owned_after":101208.0,"shares_owned_after_display":"101,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-03","filed_date":"2020-06-05","scope":"insider"},{"id":2543961,"accession":"0001209191-20-031054","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-20-031054","line_url":"/filing/0001209191-20-031054#line-7","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3907.0,"shares_display":"3,907","price_per_share":73.32,"price_display":"73.32","price_state":"stated","total_value":286461.24,"total_display":"286,461.24","shares_owned_after":101556.0,"shares_owned_after_display":"101,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-19","filed_date":"2020-05-20","scope":"insider"},{"id":2543956,"accession":"0001209191-20-031054","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-20-031054","line_url":"/filing/0001209191-20-031054#line-6","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3221.0,"shares_display":"3,221","price_per_share":73.32,"price_display":"73.32","price_state":"stated","total_value":236163.72,"total_display":"236,163.72","shares_owned_after":100944.0,"shares_owned_after_display":"100,944","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-19","filed_date":"2020-05-20","scope":"insider"},{"id":2543946,"accession":"0001209191-20-031054","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-031054","line_url":"/filing/0001209191-20-031054#line-3","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19593.0,"shares_display":"19,593","price_per_share":73.34,"price_display":"73.34","price_state":"stated","total_value":1436950.62,"total_display":"1,436,950.62","shares_owned_after":103336.0,"shares_owned_after_display":"103,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-20","scope":"insider"},{"id":2543943,"accession":"0001209191-20-031054","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-031054","line_url":"/filing/0001209191-20-031054#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2392.0,"shares_display":"2,392","price_per_share":73.29,"price_display":"73.29","price_state":"stated","total_value":175309.68,"total_display":"175,309.68","shares_owned_after":100944.0,"shares_owned_after_display":"100,944","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-20","scope":"insider"},{"id":9270853,"accession":"0001209191-19-025094","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-025094","line_url":"/filing/0001209191-19-025094#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14800.0,"shares_display":"14,800","price_per_share":70.0,"price_display":"70.00","price_state":"stated","total_value":1036000.0,"total_display":"1,036,000.00","shares_owned_after":66326.0,"shares_owned_after_display":"66,326","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-04-17","scope":"insider"},{"id":8118433,"accession":"0001209191-19-020568","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-020568","line_url":"/filing/0001209191-19-020568#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14800.0,"shares_display":"14,800","price_per_share":70.0,"price_display":"70.00","price_state":"stated","total_value":1036000.0,"total_display":"1,036,000.00","shares_owned_after":66357.0,"shares_owned_after_display":"66,357","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-20","scope":"insider"},{"id":9270852,"accession":"0001209191-19-025079","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-025079","line_url":"/filing/0001209191-19-025079#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1012.0,"shares_display":"1,012","price_per_share":65.52,"price_display":"65.52","price_state":"stated","total_value":66306.24,"total_display":"66,306.24","shares_owned_after":69125.0,"shares_owned_after_display":"69,125","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-05","filed_date":"2019-04-17","scope":"insider"},{"id":6498402,"accession":"0001209191-18-052438","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-052438","line_url":"/filing/0001209191-18-052438#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6700.0,"shares_display":"6,700","price_per_share":90.07,"price_display":"90.07","price_state":"stated","total_value":603469.0,"total_display":"603,469.00","shares_owned_after":50128.0,"shares_owned_after_display":"50,128","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-25","filed_date":"2018-09-27","scope":"insider"},{"id":6605170,"accession":"0001209191-18-036501","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-036501","line_url":"/filing/0001209191-18-036501#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6700.0,"shares_display":"6,700","price_per_share":80.068,"price_display":"80.07","price_state":"stated","total_value":536455.6,"total_display":"536,455.60","shares_owned_after":53478.0,"shares_owned_after_display":"53,478","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-07","filed_date":"2018-06-07","scope":"insider"},{"id":6904087,"accession":"0001209191-18-034281","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-034281","line_url":"/filing/0001209191-18-034281#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13000.0,"shares_display":"13,000","price_per_share":70.167,"price_display":"70.17","price_state":"stated","total_value":912171.0,"total_display":"912,171.00","shares_owned_after":57174.0,"shares_owned_after_display":"57,174","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-05-30","scope":"insider"},{"id":4539974,"accession":"0001209191-17-017612","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-017612","line_url":"/filing/0001209191-17-017612#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":90.098,"price_display":"90.10","price_state":"stated","total_value":1081176.0,"total_display":"1,081,176.00","shares_owned_after":55887.0,"shares_owned_after_display":"55,887","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-02","filed_date":"2017-03-03","scope":"insider"},{"id":4776292,"accession":"0001209191-17-015378","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-015378","line_url":"/filing/0001209191-17-015378#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":80.14,"price_display":"80.14","price_state":"stated","total_value":961680.0,"total_display":"961,680.00","shares_owned_after":51887.0,"shares_owned_after_display":"51,887","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-27","filed_date":"2017-02-28","scope":"insider"},{"id":2532953,"accession":"0001562180-16-003444","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001562180-16-003444","line_url":"/filing/0001562180-16-003444#line-6","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13600.0,"shares_display":"13,600","price_per_share":70.06,"price_display":"70.06","price_state":"stated","total_value":952816.0,"total_display":"952,816.00","shares_owned_after":55787.0,"shares_owned_after_display":"55,787","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-10","scope":"insider"},{"id":2532948,"accession":"0001562180-16-003444","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001562180-16-003444","line_url":"/filing/0001562180-16-003444#line-5","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3895.0,"shares_display":"3,895","price_per_share":71.68,"price_display":"71.68","price_state":"stated","total_value":279193.6,"total_display":"279,193.60","shares_owned_after":51892.0,"shares_owned_after_display":"51,892","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-10","scope":"insider"},{"id":2532945,"accession":"0001562180-16-003444","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001562180-16-003444","line_url":"/filing/0001562180-16-003444#line-4","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3205.0,"shares_display":"3,205","price_per_share":72.81,"price_display":"72.81","price_state":"stated","total_value":233356.05,"total_display":"233,356.05","shares_owned_after":48687.0,"shares_owned_after_display":"48,687","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-10","scope":"insider"},{"id":2532941,"accession":"0001562180-16-003444","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-16-003444","line_url":"/filing/0001562180-16-003444#line-3","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2600.0,"shares_display":"2,600","price_per_share":73.65,"price_display":"73.65","price_state":"stated","total_value":191490.0,"total_display":"191,490.00","shares_owned_after":46087.0,"shares_owned_after_display":"46,087","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-10","scope":"insider"},{"id":2532937,"accession":"0001562180-16-003444","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-16-003444","line_url":"/filing/0001562180-16-003444#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Executive Vice President)","officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700.0,"shares_display":"700","price_per_share":74.34,"price_display":"74.34","price_state":"stated","total_value":52038.0,"total_display":"52,038.00","shares_owned_after":45387.0,"shares_owned_after_display":"45,387","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-10","scope":"insider"},{"id":3053431,"accession":"0001562180-16-003255","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-16-003255","line_url":"/filing/0001562180-16-003255#line-3","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6932.0,"shares_display":"6,932","price_per_share":61.71,"price_display":"61.71","price_state":"stated","total_value":427773.72,"total_display":"427,773.72","shares_owned_after":45387.0,"shares_owned_after_display":"45,387","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-19","filed_date":"2016-10-21","scope":"insider"},{"id":3053426,"accession":"0001562180-16-003255","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-16-003255","line_url":"/filing/0001562180-16-003255#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5068.0,"shares_display":"5,068","price_per_share":60.98,"price_display":"60.98","price_state":"stated","total_value":309046.64,"total_display":"309,046.64","shares_owned_after":52319.0,"shares_owned_after_display":"52,319","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-19","filed_date":"2016-10-21","scope":"insider"},{"id":8112558,"accession":"0001562180-15-001071","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-15-001071","line_url":"/filing/0001562180-15-001071#line-3","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6723.0,"shares_display":"6,723","price_per_share":102.16,"price_display":"102.16","price_state":"stated","total_value":686821.68,"total_display":"686,821.68","shares_owned_after":47078.0,"shares_owned_after_display":"47,078","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-10","filed_date":"2015-12-14","scope":"insider"},{"id":8112554,"accession":"0001562180-15-001071","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-001071","line_url":"/filing/0001562180-15-001071#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5277.0,"shares_display":"5,277","price_per_share":101.03,"price_display":"101.03","price_state":"stated","total_value":533135.31,"total_display":"533,135.31","shares_owned_after":41801.0,"shares_owned_after_display":"41,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-10","filed_date":"2015-12-14","scope":"insider"},{"id":8892009,"accession":"0001562180-15-000584","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-15-000584","line_url":"/filing/0001562180-15-000584#line-3","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1954.0,"shares_display":"1,954","price_per_share":132.47,"price_display":"132.47","price_state":"stated","total_value":258846.38,"total_display":"258,846.38","shares_owned_after":43701.0,"shares_owned_after_display":"43,701","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-20","filed_date":"2015-07-22","scope":"insider"},{"id":8892007,"accession":"0001562180-15-000584","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-000584","line_url":"/filing/0001562180-15-000584#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1412.0,"shares_display":"1,412","price_per_share":131.56,"price_display":"131.56","price_state":"stated","total_value":185762.72,"total_display":"185,762.72","shares_owned_after":42289.0,"shares_owned_after_display":"42,289","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-20","filed_date":"2015-07-22","scope":"insider"},{"id":8892005,"accession":"0001562180-15-000584","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-15-000584","line_url":"/filing/0001562180-15-000584#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":488.0,"shares_display":"488","price_per_share":130.99,"price_display":"130.99","price_state":"stated","total_value":63923.12,"total_display":"63,923.12","shares_owned_after":41801.0,"shares_owned_after_display":"41,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-20","filed_date":"2015-07-22","scope":"insider"},{"id":8472515,"accession":"0001562180-15-000585","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-15-000585","line_url":"/filing/0001562180-15-000585#line-3","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1954.0,"shares_display":"1,954","price_per_share":132.47,"price_display":"132.47","price_state":"stated","total_value":258846.38,"total_display":"258,846.38","shares_owned_after":43701.0,"shares_owned_after_display":"43,701","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-20","filed_date":"2015-07-22","scope":"insider"},{"id":8472508,"accession":"0001562180-15-000585","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-000585","line_url":"/filing/0001562180-15-000585#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1412.0,"shares_display":"1,412","price_per_share":131.56,"price_display":"131.56","price_state":"stated","total_value":185762.72,"total_display":"185,762.72","shares_owned_after":42289.0,"shares_owned_after_display":"42,289","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-20","filed_date":"2015-07-22","scope":"insider"},{"id":8472504,"accession":"0001562180-15-000585","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-15-000585","line_url":"/filing/0001562180-15-000585#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":488.0,"shares_display":"488","price_per_share":130.99,"price_display":"130.99","price_state":"stated","total_value":63923.12,"total_display":"63,923.12","shares_owned_after":41801.0,"shares_owned_after_display":"41,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-20","filed_date":"2015-07-22","scope":"insider"},{"id":8892000,"accession":"0001562180-15-000508","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-000508","line_url":"/filing/0001562180-15-000508#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2651.0,"shares_display":"2,651","price_per_share":95.95,"price_display":"95.95","price_state":"stated","total_value":254363.45,"total_display":"254,363.45","shares_owned_after":47004.0,"shares_owned_after_display":"47,004","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-18","filed_date":"2015-06-19","scope":"insider"},{"id":8891997,"accession":"0001562180-15-000508","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-15-000508","line_url":"/filing/0001562180-15-000508#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1349.0,"shares_display":"1,349","price_per_share":96.35,"price_display":"96.35","price_state":"stated","total_value":129976.15,"total_display":"129,976.15","shares_owned_after":45655.0,"shares_owned_after_display":"45,655","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-18","filed_date":"2015-06-19","scope":"insider"},{"id":8342623,"accession":"0001562180-15-000386","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-15-000386","line_url":"/filing/0001562180-15-000386#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":79.43,"price_display":"79.43","price_state":"stated","total_value":317720.0,"total_display":"317,720.00","shares_owned_after":45255.0,"shares_owned_after_display":"45,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-18","filed_date":"2015-05-20","scope":"insider"},{"id":8706116,"accession":"0001562180-15-000301","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-15-000301","line_url":"/filing/0001562180-15-000301#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":62.59,"price_display":"62.59","price_state":"stated","total_value":187770.0,"total_display":"187,770.00","shares_owned_after":48255.0,"shares_owned_after_display":"48,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-20","filed_date":"2015-04-22","scope":"insider"},{"id":8706115,"accession":"0001562180-15-000301","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-15-000301","line_url":"/filing/0001562180-15-000301#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":61.14,"price_display":"61.14","price_state":"stated","total_value":61140.0,"total_display":"61,140.00","shares_owned_after":51255.0,"shares_owned_after_display":"51,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-20","filed_date":"2015-04-22","scope":"insider"},{"id":8896754,"accession":"0001182489-15-000421","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-15-000421","line_url":"/filing/0001182489-15-000421#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":61.45,"price_display":"61.45","price_state":"stated","total_value":245800.0,"total_display":"245,800.00","shares_owned_after":52255.0,"shares_owned_after_display":"52,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-18","filed_date":"2015-03-20","scope":"insider"},{"id":8074642,"accession":"0001182489-15-000352","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001182489-15-000352","line_url":"/filing/0001182489-15-000352#line-2","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3704.0,"shares_display":"3,704","price_per_share":53.9253,"price_display":"53.93","price_state":"stated","total_value":199739.3112,"total_display":"199,739.31","shares_owned_after":56255.0,"shares_owned_after_display":"56,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-18","filed_date":"2015-02-20","scope":"insider"},{"id":8074639,"accession":"0001182489-15-000352","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-15-000352","line_url":"/filing/0001182489-15-000352#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":296.0,"shares_display":"296","price_per_share":54.7168,"price_display":"54.72","price_state":"stated","total_value":16196.1728,"total_display":"16,196.17","shares_owned_after":59959.0,"shares_owned_after_display":"59,959","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-18","filed_date":"2015-02-20","scope":"insider"},{"id":8209440,"accession":"0001182489-15-000072","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-15-000072","line_url":"/filing/0001182489-15-000072#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":51.2393,"price_display":"51.24","price_state":"stated","total_value":204957.2,"total_display":"204,957.20","shares_owned_after":60255.0,"shares_owned_after_display":"60,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-20","filed_date":"2015-01-22","scope":"insider"},{"id":6941634,"accession":"0001182489-14-001234","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-14-001234","line_url":"/filing/0001182489-14-001234#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":44.8224,"price_display":"44.82","price_state":"stated","total_value":179289.6,"total_display":"179,289.60","shares_owned_after":64255.0,"shares_owned_after_display":"64,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-12-18","filed_date":"2014-12-22","scope":"insider"},{"id":6787073,"accession":"0001182489-14-001129","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-14-001129","line_url":"/filing/0001182489-14-001129#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":44.0703,"price_display":"44.07","price_state":"stated","total_value":176281.2,"total_display":"176,281.20","shares_owned_after":68255.0,"shares_owned_after_display":"68,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-20","filed_date":"2014-11-21","scope":"insider"},{"id":6730428,"accession":"0001182489-14-001039","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-14-001039","line_url":"/filing/0001182489-14-001039#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":46.02,"price_display":"46.02","price_state":"stated","total_value":184080.0,"total_display":"184,080.00","shares_owned_after":72255.0,"shares_owned_after_display":"72,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-20","filed_date":"2014-10-22","scope":"insider"},{"id":6835214,"accession":"0001182489-14-001001","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-14-001001","line_url":"/filing/0001182489-14-001001#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":56.0,"price_display":"56.00","price_state":"stated","total_value":224000.0,"total_display":"224,000.00","shares_owned_after":76255.0,"shares_owned_after_display":"76,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-09-18","filed_date":"2014-09-19","scope":"insider"},{"id":6437283,"accession":"0001182489-14-000909","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001182489-14-000909","line_url":"/filing/0001182489-14-000909#line-1","is_derivative":false,"issuer_cik":"0001377202","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001377202","owner_cik":"0001377202","owner_name":"Sharp Shalini","owner_url":"/insider/0001377202","role":"Officer (CFO & Senior Vice President)","officer_title":"CFO & Senior Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":53.97,"price_display":"53.97","price_state":"stated","total_value":215880.0,"total_display":"215,880.00","shares_owned_after":80255.0,"shares_owned_after_display":"80,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-18","filed_date":"2014-08-19","scope":"insider"}],"next_cursor":"2014-08-18|6437283","ledger_fault":false,"count":{"value":69,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":66,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":69},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000914475","name":"NEUROCRINE BIOSCIENCES INC","url":"/issuer/0000914475","role":"Director","n_filings":1,"first_seen":"2024-05-21","last_seen":"2024-05-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (EVP, Finance)","n_filings":29,"first_seen":"2014-02-03","last_seen":"2020-10-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001098972","name":"AGENUS INC","url":"/issuer/0001098972","role":"Director, Officer (CFO)","n_filings":13,"first_seen":"2007-03-14","last_seen":"2013-02-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001377202","retrieved_at":"2026-08-22T04:38:22+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}